Radiopharmaceutical firm Neoprobe's subsidiary Biosonix has received Food and Drug Administration clearance for its FlowGuard blood-flow evaluation product. FlowGuard, which received CE mark clearance from European regulatory agencies in late 2001, has been cleared in the U.S. for use in determination of blood flow in non-invasive diagnostic and intraoperative applications, according to Neoprobe of Dublin, OH.
By AuntMinnie.com staff writersFebruary 28, 2002
Related Reading
Neoprobe reports second year of profitability, February 25, 2002
Neoprobe closes Biosonix purchase, January 4, 2002
Neoprobe moves closer to Biosonix purchase, December 11, 2001
Biosonix gets CE mark for FlowGuard, October 4, 2001
Neoprobe to buy Biosonix, September 7, 2001
Copyright © 2002 AuntMinnie.com
